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The bone marrow microenvironment is physiologically hypoxic with areas being as low as 1% O2, 
e.g. the stem cell niche. Acute myeloid leukaemia (AML) blasts misuse these bone marrow niches for 
protection by the local microenvironment, but also might create their own microenvironment. Here 
we identify IL-8 as a hypoxia-regulated cytokine in both AML cell lines and primary AML samples that 
is induced within 48 hours of severe hypoxia (1% O2). IL-8 lacked effects on AML cells but induced 
migration in mesenchymal stromal cells (MSC), an integral part of the bone marrow. Accordingly, MSC 
were significantly increased in AML bone marrow as compared to healthy bone marrow. Interestingly, 
mononuclear cells obtained from healthy bone marrow displayed both significantly lower endogenous 
and hypoxia-induced production of IL-8. IL-8 mRNA expression in AML blasts from 533 patients differed 
between genetic subgroups with significantly lower expression of IL-8 in acute promyelocytic leukaemia 
(APL), while in non APL-AML patients with FLT ITD had the highest IL-8 expression. In this subgroup, 
high IL-8 expression was also prognostically unfavourable. In conclusion, hypoxia as encountered in the 
bone marrow specifically increases IL-8 expression of AML, which in turn impacts niche formation. High 
IL-8 expression might be correlated with poor prognosis in certain AML subsets.
Recent evidence suggests that in acute myeloid leukaemia (AML) the microenvironment is an important part of 
disease progression and pathophysiology1. Exact mechanisms remain elusive, if nothing else due to the fact that 
the bone marrow is a complex tissue and this microenvironment comprises a multitude of different components 
existing in an intricate network (and as the name says: it is rather small). These components can be either cellular 
or non-cellular.
Cellular components are haematological (monocytes or blasts to name a few) or non-haematological cells (e.g. 
mesenchymal stromal cells [MSC]) residing in the bone marrow. MSC are a part of the stem cell niche, which is 
commonly referred to as the microenvironment in the context of AML. They are rather well understood, and they 
influence AML blasts in a variety of ways, e.g. by induction of metabolic changes2,3 or regulation of anti-apoptotic 
proteins4. Non-cellular components are even more diverse, and comprise of biological (e.g. cytokines) and 
physico-chemical features (e.g. O2). Due to the low solubility of O2 in tissue the bone marrow is hypoxic (i.e. ≤ 6% 
O2, depending on the region), which has been shown beyond doubt5–7. The functional impact of O2 however is less 
clear, but hypoxia has been shown to impact differentiation of normal haematological progenitors8 and expression/ 
phosphorylation of proteins in AML5,6,9.
While the effects of the microenvironment and parts thereof on AML have been extensively investigated, little 
attention has been paid to the effects AML exerts on the microenvironment. There are several studies of cytokine 
production of AML10,11, which can been considered a part of the microenvironment, but the biological conse-
quences are unclear and are mostly considered as a mechanism for autocrine stimulation. Additionally, each part 
of the microenvironment has been looked at separately, which rather reflects a methodological problem than the 
underlying biology.
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Hence, this project aimed to elucidate a factor that interlinks the cellular with the non-cellular microenvi-
ronment. This factor would most likely be a cytokine produced by AML, and to effectively combine the different 
components of the microenvironment, it would need to fulfil 2 requirements: (I) it has to be regulated by hypoxia 
and (II) in turn it should influence niche formation (i.e. MSC). Preliminary data suggested IL-8 (CXCL8) to be 
upregulated in AML by hypoxia, fulfilling the first prerequisite, while published data pointed on its influence on 
MSC (i.e. migration12), fulfilling the second requirement. Thus, it is an ideal candidate for further research.
Results
Presence of mesenchymal stromal cells is increased in AML bone marrow. Mesenchymal stromal 
cells (MSC) are an integral part of the microenvironment in the bone marrow. Hence, in a first step we examined 
whether AML bone marrow differs in MSC presence from normal bone marrow. We investigated 8 random 
normal bone marrows and compared these to 8 random AML bone marrows for the staining of CD90+ , CD10+ 
cells with a distinct morphology. As shown in Fig. 1, CD90+ and CD10+ cell density was visually markedly 
higher in AML bone marrow as compared to normal bone marrow (Fig. 1A: 2 representative samples each). 
CD90+ and CD10+ cells per high power field (HPF, 1000fold magnification, 2 replicates each) were also sig-
nificantly higher in AML samples (Fig. 1B: CD90+ : 19.0 vs. 3.5, p < 0.01, CD10+ : 39.0 vs. 18.6, p < 0.05).There 
was no significant difference in CD31+ cells (4.2 vs. 4.2, p = 0.19, Fig. 1A and B), a marker for endothelial cells, 
which are also positive for CD90. Hence, the CD90+ cells increased in AML samples are not endothelial cells. As 
samples were fully anonymized, no clinical data was available for these patients.
Regulation of cytokines by hypoxia in AML. As AML blasts and MSC might interact via cytokines, we 
performed a screening assay for 80 cytokines in the supernatant of AML cell lines. In this screening, only IL-8 and 
HGF showed a significant (semi quantitative) increase at hypoxic conditions and were therefore further investi-
gated (data not shown). As shown in Fig. 2, IL-8 and HGF secretion was measured during different time points 
(2 and 10 days) and at different oxygen levels (21%, 12%, 6% and 1%) in AML cell lines Kg1a and OCI-AML3. 
Here we found that, despite significant differences in IL-8 production between the cell lines (Kg1a 0.5 pg/mL 
Figure 1. AML bone marrow has increased numbers of mesenchymal stromal cells as compared to normal 
bone marrow. (A) 2 representative samples each for normal bone marrow and AML (CD90, CD10 and CD31 
staining, 630fold magnification). (B) Absolute numbers of CD90+ and CD10+ cells (MSC) were significantly 
increased in HPF (1000fold magnification) in AML bone marrow, while there was no difference for CD31+ 
cells (endothelial cells).
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versus OCI-AML3 20.1 pg/mL [p < 0.01, mean standardized to 105 viable cells/mL]) after 48 hours IL-8 secretion 
was significantly increased in both cell lines at 1% O2 only, while the effects of both 12% and 6% O2 did not differ 
from IL-8 secretion at standard laboratory conditions of 21% O2 (increase as compared to 21% O2: Kg1a: 12% 
0.96fold [n.s.], 6% 1.48fold [n.s.], 1% 2.61fold [p < 0.05]; OCI-AML3 12% 0.92fold [n.s.], 6% 1.27fold [n.s.], 1% 
8.62fold [p < 0.01]). Similarly, both cell lines maintained this increased production of IL-8 even when adapted 
to the respective level of hypoxia for up to 10 days. We also observed that at 6% O2 IL-8 production was already 
slightly increased in OCI-AML3 (pg/mL per 105 cells; Kg1a 21% 0.76, 12% 1.14 [n.s.], 6% 1.86 [n.s.], 1% 6.57 
[p < 0.05]; OCI-AML3 21% 15.11 12% 17.83 [n.s.], 6% 27.70 [p < 0.05], 1% 99.37 [p < 0.01]). However, we were 
unable to detect any differences for HGF and hence abandoned further investigation of this cytokine, focusing on 
IL-8 instead for further experiments.
Figure 2. Hypoxia mediated cytokine secretion in AML cell lines. (A) In Kg1a, only profound hypoxia of 1% 
O2 significantly increases IL-8 secretion after 48 hours as compared to 21% O2. (B) Similar results were obtained 
in OCI-AML3 cell line. (C) Kg1a cells adapted to hypoxia for 8 days maintain increased secretion of IL-8.  
(D) Il-8 secretion of hypoxia adapted OCI-AML3 cells. (E) No significant increase of HGF production in both 
AML cell lines.
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Hypoxia induced expression of IL-8 in AML. Next, we confirmed the results of AML cell lines in primary 
AML samples. For these experiments, a time point of 48 hours and 1% O2 were chosen based on the previous 
results. Patient samples from 22 patients with AML were available (median age 69 [22–82] years, male 45%). IL-8 
secretion was profoundly higher in primary AML samples as compared to AML cell lines (after 48 hours: 7.8 ± 9.1 
[for Kg1a and OCI-AML3] versus 459.1 ± 644.4 pg/ml, p < 0.01), and induction of IL-8 expression at hypoxia of 
1% O2 was also confirmed in the primary samples (2fold, p < 0.01: Fig. 3A).
Next, we performed subgroup analyses concerning differential expression and hypoxia induced induction of 
IL-8 in genetically defined AML patients. FLT3 wild type and FLT3-ITD patients did not differ significantly at 
their baseline secretion of IL-8 at 21% O2 (258.5 pg/ml per 105 FLT3 wild type cells versus 300.1 pg/ml per 105 
Figure 3. Hypoxia induced expression of IL-8 in AML. (A) In primary samples of patients with AML 
(n = 22), hypoxia increases secretion of IL-8 by 2fold. (B) FLT3 mutational status did not influence IL-8 
secretion. (C) Normal hematopoietic progenitors (MNC mononuclear cells) produce significantly less IL-8 at 
hypoxic conditions than AML. (D) Healthy hematopoietic progenitors do not induce IL-8 at hypoxia.  
(E) Hypoxia increases IL-8 mRNA in AML cell lines OCI-AML3 and KG-1a.
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FLT3 ITD cells) nor did they differ in hypoxia mediated induction of IL-8 (2.3fold versus 1.7fold, Fig. 3B). Similar 
results were obtained for NPM1 (250.2 pg/ml and 2.9fold induction by hypoxia, not significant). Interestingly, 
secretion of IL-8 of FICOLL density centrifugation enriched mononuclear cells from the bone marrow of healthy 
individuals (n = 4) was significantly lower than that of AML blasts after 48 hours at 1% O2 in vitro (548.0 pg/ml 
versus 62.8 pg/ml, p < 0.01 [Mann-Whitney-test], Fig. 3C). In addition, these healthy hematopoietic progenitors 
showed no significant increase of IL-8 under hypoxia (p = 0.17, Fig. 3D). Hypoxia induced increase of IL-8 secre-
tion was due to increased translational processing, as IL-8 PCR revealed significantly increased levels of mRNA 
for IL-8 after 48 hours of 1% O2 as compared to 21% O2 in AML cell lines OCI-AML3 and KG-1a (Δ Δ CT 3.50 for 
OCI-AML3 and 1.95 for KG-1a, p < 0.01; Fig. 3E).
Effects of IL-8 on AML and the microenvironment. We next examined the effects of IL-8 on AML 
blasts for possible autocrine mechanisms. First, expression of IL-8 receptor alpha (CXCR1) and beta (CXCR2) on 
AML cell lines was investigated. CXCR1, considered more specific for IL-8 was absent on all 9 cell lines (CMK, 
HEL, HL60, Kg-1a, Molm13, MonoMac6, MV4/11, NB4, OCI-AML5) investigated, and “promiscuous” CXCR2 
(also having affinity for CXCL1, 2, 3, 5, 6, 7 and 8) was also absent on the majority (6 out of 9) of these cell lines 
(Fig. 4A) and hypoxia did not affect the expression of both IL-8 receptors (data not shown). We then investigated 
whether IL-8 could have an impact on the cellular microenvironment instead of auto- or paracrine stimulation 
and found that out of all primary MSC investigated (n = 4, 2 from healthy volunteers and 2 from AML patients) 
a median of 9.7% of cells expressed IL-8 receptor CXCR1 on their surface, independently of the oxygen state 
they were in (increase 1.15fold in % positive cells, Fig. 4B). In addition, CXCR1 and CXCR2 mRNA expression 
(median 9.17 ± 0.38 versus 6.15 ± 0.85, p < 0.001) in 533 AML patients (for details, see section 3.5), while highly 
correlated with each other (r = 0.43, p < 0.001 [Pearson]) had no impact on overall (Hazard ratios [HR]: CXCR1 
0.91 [95 CI 0.68–1.21], CXCR2 HR 0.96 [0.84–1.09]) and relapse free survival (HR: CXCR1 0.96 [0.65–1.4], 
CXCR2 1.02 [0.87–1.21]). Also, median expression did not separate prognostic groups as described previously 
(median OS for CXCR1 316 days (≤ median) versus 374 days (> median) [n.s.], for CXCR2 342 days (≤ median) 
versus 344 days (> median) [n.s.]).
According to this low to absent expression of IL-8 receptors in AML, cell line MV4/11 (displaying the highest 
CXCR2 expression) did not migrate towards increasing doses of chemokine IL-8 in transwell experiments (Fig. 4C, 
similar results for Molm13, Kg1a and OCI-AML3 are not shown). Instead, primary MSC from the bone marrow 
migrated towards IL-8 (1.45 fold, p < 0.01, Fig. 4D). These data implicate an effect of IL-8 on MSC rather than the 
myelopoiesis. Interestingly, migration of MSC could be abrogated by inhibition of protein kinase C zeta (PKCζ ) 
by 5 μ M of PKCζ pseudosubstrate.
However, when serum levels of IL-8 in patients with AML (n = 4 with at least 3 serum specimen at 1 time point 
available) that were undergoing intensive chemotherapy (with sequential high-dose AraC and mitoxantrone as 
induction chemotherapy13 were examined, it was interesting to observe that at initial diagnosis with high leukemic 
burden and granulocytopenia, serum levels of IL-8 were lowest (40 pg/mL), increasing during aplasia (maximum 
of 210 pg/mL after 4 weeks) and then decreasing to lower levels after achievement of CR and recovery of peripheral 
blood count (88 pg/mL, Fig. 4E).
Clinical impact of IL-8 RNA expression. In addition, we analysed the expression of IL-8 in leukemic 
blasts from 533 AML patients that were treated within the AMLCG1999 trial14. For details of trial treatment, 
please refer to the publication. Patients of the cohort investigated had an average age of 55.2 years (18–85 years), 
50.3% of them were male. Of these patients, 26.5% were grouped into the favourable subgroup according to 
European Leukemia Net15, 20.8% into the intermediate I and 20.1 into the intermediate II subgroup. 25.1% 
belonged to the unfavourable subgroup. In 7.5% classification according to ELN was not possible. In 126 patients 
(23.6%) a FLT-ITD mutation was found. 289 patients (54.0%) achieved a complete remission. In addition, we had 
RNA expression and clinical data from 29 patients with acute promyelocytic leukaemia (APL). The median age of 
this cohort was 51 years (21 – 83 years), 12 patients were male and CR was achieved in 81%.
In the full cohort of patients (AML and APL patients combined), higher levels of IL-8 were found to profoundly 
impact overall survival (OS) and relapse free survival (RFS). Hazard ratio (HR) was 1.11 (1.03–1.20, p < 0.01) for 
OS and 1.13 (1.02–1.26, p < 0.05) for RFS. However, this effect was lost when only non APL-AMLs were analysed 
(HR: OS: 1.04 [0.96–1.14], n.s., RFS 1.04 [0.93–1.17], n.s.), the reason being a significant lower expression of IL-8 
in APL than non APL-AML (Fig. 5A). However, the 10% patients with non APL-AML that displayed the highest 
expression (cut-off 13.08) did still have a shorter OS (median 5.7 months vs. 12.0 months, p < 0.01 [log-rank], 
Fig. 5B). This effect might be attributable to the significant association of IL-8 mRNA with peripheral leukocyte 
count (a well-established prognostic factor) at initial diagnosis (Fig. 5C) or differential expression of IL-8 in prog-
nostic subgroups. We therefore analysed the expression of mRNA IL-8 expression of leukemic blasts in different 
genetically defined subgroups of non APL-AML patients. Interestingly, while there was no difference in IL-8 mRNA 
between NPM1 wild type (n = 178; 11.84 ± 1.2,) and NPM1 mutated samples (n = 116, 12.1 ± 1.0, not signifi-
cant), the presence of a FLT3-ITD (n = 126) was associated with increased mRNA expression in the AML blasts 
(12.1 ± 1.0 versus 11.8 ± 1.3 for FLT wild type [n = 396], p < 0.05). Next, we analysed whether IL-8 expression had 
any particular effect according to FLT3 mutational status. While there was no effect on survival parameters in the 
FLT3 wild type cohort (n = 396), using Cox regression a significant impact of IL-8 expression was noted within 
the FLT3-ITD group (n = 124) on OS (HR 1.34 [1.01–1.78], p < 0.05) and RFS (HR 1.49 [1.02–2.19], p < 0.05). 
As a cut-off we chose the median of IL-8 mRNA in this group, and found that this threshold was predictive for OS 
(Fig. 5D, borderline significance) and RFS (Fig. 5E).
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Discussion
The microenvironment of the bone marrow emerges as a critical player in cancer biology. However, mostly isolated 
parts of the microenvironment have been investigated, in the case of AML e.g. either MSC4,16 or bone marrow 
hypoxia5,6 and their effects on AML blasts. In this study, we tried to identify components that link different parts 
of the microenvironment and also AML to each other and found IL-8 (CXCL8) to be such a possible missing link.
CXCL8 has long been identified as a pro-inflammatory cytokine and a strong chemoattractant for neutrophils17. 
Besides this physiological function, environmental stresses, such as hypoxia, acidosis, chemotherapy, etc. have 
Figure 4. Effects of IL-8 in AML and on the microenvironment. (A) While IL-8 receptor CXCR1 is not 
expressed on 9/9 AML cell lines, in 3/9 cell lines IL-8 receptor CXCR2 is expressed on 26.5–49.6% of cells.  
(B) App. 10% of primary MSC express IL-8 receptor CXCR1 on their surface but no IL-8 receptor CXCR2. 
Expression is independent from pO2. (C) MV4/11 cells do not migrate against IL-8 in transwell experiments 
(1% FCS: positive control). (D) Primary bone marrow derived MSC (n = 3) however do significantly migrate 
towards an IL-8 gradient. This migration can be abrogated by inhibition of PKCζ . (E) IL-8 serum levels in 
patients with AML undergoing intensive chemotherapy (grey bar: period of induction chemotherapy with 
sequential high dose cytarabine and mitoxantrone).
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been attributed to induction of IL-8 in tumour tissue18. In addition, constitutional elevated levels of CXCL8 have 
been observed various cancers, e.g. prostate19, colorectal20 and non-small cell lung cancer21. Two receptors for 
CXCL8 have been identified, the more specific CXCR1 and the more “promiscuous” CXCR2 that also binds other 
CXC ligands (1, 2, 3, 5, etc.)18. After ligand binding of these G-protein-coupled receptors, a range of intracellular 
signalling pathways are activated, including MAPK, PI3K, PKC, FAK and Src18, which confer at least in part to 
diminished apoptosis and increased proliferation. Indeed, CXCL8 was shown to induce chemo resistance against 
oxaliplatin and also etoposide in solid tumours18.
Figure 5. Clinical impact of IL-8 mRNA expression in AML. (A) Significant lower (semi-quantitative) levels 
of IL-8 mRNA in APL cells as compared to non APL-AML cells (p < 0.01). (B) IL-8 mRNA expression in AML 
blasts above the 10th percentile confers a significant worse OS in AML patients. (C) IL-8 mRNA levels were 
significantly correlated with peripheral leukocyte count at initial diagnosis. (D) In FLT3-ITD patients (n = 124), 
IL-8 mRNA levels above the median tend to confer a decreased survival (borderline significance). (E) For RFS 
this cut-off value significantly divided the FLT3-ITD population.
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However, little is known about the role of IL-8 in AML. The overexpression of the chemokine in AML has been 
known for over 20 years22 and has recently been confirmed23. We also found IL-8 to be constantly expressed in 
AML, albeit with differences in genetic defined subtypes: we found the lowest expression of mRNA in APL and the 
highest expression in AML with FLT-ITD – which might also explain prognostic differences associated with IL-8 
expression. However, we were unable to observe differences in IL-8 protein secretion in vitro by different AML 
subgroups, but this is most likely owed to the fact that the number of patient samples was too small and hence 
underpowered for the detection of this difference. In addition, we found that IL-8 mRNA in AML blasts correlated 
to initial blast count, an old but well established risk factor24,25 and IL-8 was of prognostic significance in the cohort 
of patients harbouring a FLT-ITD mutation. But if we assume a general biological role for IL-8 in AML, maybe 
even a conditio sine qua non, it is not quite so surprising that no strong impact on prognosis is observed as poten-
tially all AML are dependent on it. The course of serum levels of IL-8 in AML patients - correlating with leukocyte 
burden (but not with AML blasts) - suggests however that IL-8 is not solely produced by AML but rather related 
to healthy myelopoiesis. However, questions remain concerning which cells actually produce this serum IL-8 in 
vivo and whether there are differences in IL-8 concentrations between the bone marrow and the peripheral blood. 
It should of course not be forgotten that IL-8 is an inflammatory cytokine in the first place, and hence this increase 
might simply reflect the fact that patients in aplasia after chemotherapy suffer from infections due to neutropenia, 
which are known to increase IL-8 levels26,27.
The induction of IL-8 by hypoxia has been described in solid tumours28, and IL-8 is indeed considered a down-
stream target of HiF1α 29. This increase by hypoxia has always been attributed to environmental stress, but our data 
do not support this notion in the case of AML. Hypoxia of 1% O2 is considered physiological in the stem cell niche8, 
and the whole bone marrow is considered to be hypoxic5. The investigated cells were not stressed functionally by 
this low oxygen level (no impaired viability) and IL-8 was the only cytokine upregulated by hypoxia and the upreg-
ulation was quite specifically time and dose dependent. As expected, IL-8 expression was transcriptionally regulated 
by hypoxia. Interestingly, we observed a significant difference between normal mononuclear bone marrow cells and 
AML blasts: normal cells expressed significantly lower IL-8 protein and did not show an upregulation by hypoxia.
The role of IL-8 receptors remain elusive: one recent publication found CXCR2 to be overexpressed in AML on 
a mRNA level, but did not show direct expression by e.g. flow cytometry or microscopy. They additionally found a 
significantly higher expression of CXCR2 mRNA than CXCR1 mRNA and also a prognostic impact in 200 AML 
samples23. We however were unable to confirm these findings on our much larger cohort of 533 patients. Median 
CXCR1 mRNA was significantly higher in our cohort than CXCR2 and neither had any prognostic impact. We 
also found actual CXCR2 expression measured by FACS in only 30% of AML cell lines. While we can only explain 
these differences by different methods (mRNA versus flow cytometry) and different AML patient collectives, based 
on our data we would like to propose a different mechanism for IL-8 in the context of AML: no auto- or parakrine 
stimulation of AML but instead, modulation of the microenvironment by AML blasts; and while a proangiogenic 
effect of IL-8 – angiogenesis being microenvironment as well–has been well established30, in our hypothesis, the 
affected microenvironment would be mesenchymal stromal cells.
Indeed, we found that bone marrow derived MSC (I) expressed CXCL1 but not CXCL2 and that (II) primary 
MSC migrated towards an IL-8 gradient in vitro, confirming previous reports12. Now, given that the production 
of IL-8 by AML blasts (but not normal mononuclear cells from the bone marrow) is stimulated by the pO2 present 
in the stem cell niche one would assume that MSC density in AML bone marrow is increased when compared to 
normal bone marrow and this is exactly what we observed. The effects of MSC on AML have been well established 
meanwhile and need not be reviewed here again in detail. They are mostly chemo-protective, e.g. by upregulation 
of anti-apoptotic proteins4 or metabolic changes2,3.
As the CXCL8-IL8 receptor axis has been identified as an drugable target in e.g. diseases with chronic inflamma-
tion, several mechanisms have been developed to inhibit it. One way is direct inhibition via neutralizing antibodies 
for CXCL8, which were mainly developed for the treatment of inflammatory diseases like chronic obstructive 
pulmonic disease, but which also did show promising results in pre-clinical melanoma models31. In addition, 
small molecules have been developed that antagonize CXCR1/2 signalling. Here, CXCR1 blockade by reparixin 
has shown promising activity against breast cancer in mouse xenografts models32 and CXCR1/2 inhibition by 
SCH-527123 did reduce tumour growth and microvessel density in a xenograft model of colorectal cancer33. While 
clinical data about the anti-cancer efficacy of these drugs are missing, the data available from clinical trials have 
proven the safety and feasibility of these drugs18.
In conclusion, this data supports the importance of IL8 in AML but provides an additional novel mechanism: 
IL-8 could be the missing link that ties MSC and hypoxia in AML together. As the means of inhibition of the 
CXCL8-IL-8 receptor axis are at hand, further studies on the therapeutic intervention seem warranted and may 
utilize a novel concept in AML therapy: to aim at the crucial AML microenvironment interaction rather than the 
leukemic cell itself.
Methods
Immunohistochemistry of bone marrow biopsies. Immunohistochemical analyses were performed 
on archival bone marrow trephine biopsies taken from the iliac crest after informed consent had been obtained 
from the patients. Diagnosis of AML was confirmed according to WHO criteria (≥ 20% myeloid blasts with 
> 3% positivity for peroxidase). Eight samples of patients with AML were used; these samples were completely 
anonymized for analysis, hence no further information on these patients is available. Eight normal controls con-
sisted of patients without bone marrow involvement; again, these patients were anonymized and no further infor-
mation was made available. After formalin-fixation, these specimens had been mildly decalcified overnight in 
acetic acid, and embedded in paraffin wax. Sections were cut at 3 μm and stained for CD90 (Acris, San Diego, 
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USA), CD10 (Ventana Medical Systems, Tucson, AZ, USA) and CD31 (Dako, Hamburg, Germany) by the indi-
rect immunoperoxidase-staining technique as described elsewhere34.
Cell culture. Standard laboratory (normoxic) conditions comprised 21% O2, 5% CO2, and 37 °C. For exper-
iments in a reduced oxygen environment, the hypoxic Workstation INVIVO2 400 from Ruskinn Technology 
(Bridgend, United Kingdom) was used. Cells were incubated at 12%, 6% or 1% O2, 5% CO2, and 37 °C. Live cell 
numbers were evaluated by trypane blue exclusion (Life Technologies, Darmstadt, Germany).
AML cell lines were all obtained from the DSMZ (German collection of Microorganisms and Cell Cultures, 
Braunschweig, Germany). Cell lines were maintained at a density of 2.0 × 105/ml in RPMI 1640 contain-
ing 10% FCS (Biochrom, Berlin, Germany), 2 mM glutamine and 1% penicillin-streptomycin (all from Life 
Technologies, Darmstadt, Germany). Primary AML samples were collected from bone marrow aspirates or from 
peripheral blood from AML patients who underwent routine diagnostics. Mononuclear cells were separated by 
Ficoll-Hypaque (Sigma-Aldrich, St Louis, MO) density-gradient centrifugation and cultured at a density of 106/
ml in RPMI 1640 containing 10% FCS, 2 mM glutamine and 1% penicillin-streptomycin. Experiments were per-
formed on fresh and frozen cells. All experiments were carried out in accordance with approved guidelines and 
regulations. All experimental procedures were approved by the local ethics committee (Medical Faculty of the 
Ludwig-Maximilians-Universität, Munich, Germany).
Enzyme-linked immunosorbent assay (ELISA) and cytokine array. Supernatant of primary AML 
cells (106/ml) or AML cell lines KG-1a and OCI-AML-3 (2.0 × 105/ml) were collected after 48 h of in vitro cul-
tivation at the indicated oxygen concentration by centrifugation (10 min, 2000 rpm). For long term cultures cell 
lines were pre-cultured under hypoxic conditions for 8 days prior to this treatment. IL-8 and HGF protein in the 
supernatant was quantified with the human IL-8 ELISA Kit II (BD Biosciences, San Jose, USA) and human HGF 
ELISA (R&D Systems, Minneapolis, USA) according to the manufacturer’s instructions. For quantification of 
IL-8 protein in patients with AML, serum samples were collected during routine surveillance at the indicated 
time points and spun down at 2000 rpm for 10 minutes. Serum was stored at − 80 °C and IL-8 quantification was 
performed by ELISA as described.
Flow cytometry. Primary AML cells or AML cell lines were cultured at the respective conditions, collected 
by centrifugation after the indicated time points and stained with anti-human fluorescence labelled antibod-
ies CXCR1 APC and CXCR2 FITC (all from BD Biosciences, San Jose, USA) according to the manufacturer’s 
instructions with appropriate isotype controls. Flow cytometry was performed with a FACSCalibur cytometer 
(BD Biosciences, San Jose, USA) and data was analysed with BD CellQuest software.
IL-8 PCR. AML cell lines KG-1a and OCI-AML-3 were collected after 5 days of culture at the appropriate oxy-
gen conditions and total RNA was extracted with the Absolutely RNA Mini Prep Kit (Agilent Technologies, Santa 
Clara, USA) following the manufacturer’s instructions. For RT-PCR the First-Strand cDNA Synthesis System (Life 
Technologies, Carlsbad, USA) with the supplied oligo-(dT)20 primer was applied. Quantitative PCR amplifications 
were performed using Fast SYBR Green Master Mix (Applied Biosystems, Waltham, USA) on the 7900HT Fast 
Real Time PCR system from the same company. For IL-8 cDNA amplification the following primers were used: 
human IL-8 forward 5′ -TAGCAAAATTGAGGCCAAGG-3′ and reverse 5′ -AGCAGACTAGGGTTGCCAGA-3′ 
(Biomol GmbH, Hamburg Germany). ß-actin was used as housekeeping gene: human ß-actin forward 
5′ -CCGAGGACTTTGATTGCACA-3′ and reverse 5′ -AGTGGGGTGGCTTTTAGGAT-3′ . (MWG Biotech, 
Ebersberg Germany). PCR conditions were: 95 °C for 15 min followed by 40 cycles of 95 °C for 15 sec, 60 °C for 
30 sec, and 72 °C for 30 sec. Fold of RNA induction relative to normoxic conditions was calculated as the mean 
2eΔΔCt of n = 4 independent experiments.
Migration assay. Migration of cell lines was assessed in Transwell permeable 24 well plates with 5.0 μ M 
pores (Costar, Washington USA). The lower compartment contained 500 μ L of serum free media supplemented 
with indicated concentrations of IL-8 (R&D Systems, MN, USA), while 105 cells were placed in the upper com-
partment. After 24 hrs the amount of viable cells migrated to the lower compartment was determined by trypan 
blue exclusion cell counting in at least three independent experiments. Migration of MSCs was assessed in 
Transwell permeable 96 well plates with 8.0 μ M pores using the fluorimetric QCM Cell Migration Assay Kit 
(Millipore, Billerica MA, US). The lower compartment contained 150 μ L of serum free media supplemented with 
IL-8. 5 × 104 primary MSC were applied to the upper compartment and allowed to migrate for 16 hrs. The amount 
of migrated cells was determined according to the manufactures instructions at 480/520 nm using Cytofluor 4000 
Fluorescence/Bioluminescence Plate Reader (Applied Biosystems, Waltham, USA). MYR PKCζ pseudosubstrate 
was from Life Technologies (Darmstadt, Germany).
Microarray analyses. Pre-treatment bone marrow samples of 562 patients at time of diagnosis were ana-
lysed using Affymetrix U133A + B and Affymetrix U133 Plus2.0 microarrays (Affymetrix, Santa Clara, CA) 
as published previously35. The microarray data have been deposited in the Gene Expression Omnibus with the 
accession number GSE3764236. Expression data are presented as log2 throughout the study.
Statistical analysis. Results are shown as the mean ± SEM or SD of at least 3 experiments each. Paired data 
were analysed using the paired Student t test. If other tests were used, they are specified at the according section. 
For survival analyses, Cox regression and the method of Kaplan-Meier using Log Rank test with SPSS Statistics® 
www.nature.com/scientificreports/
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(Version 22, IBM) were used. Microsoft Excel was used for data acquisition and storage. A P value < 0.05 was 
considered statistically significant.
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